Company · array-biopharma-b2595afc
Array BioPharma
4 sourcescompanies-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. Array BioPharma. Companies, record array-biopharma-b2595afc. Release companies-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/companies/array-biopharma-b2595afc
On this page
Company
The name as ClinicalTrials.gov gives it. A company is a name ClinicalTrials.gov classes as industry, and spellings that differ only in case or spacing are one; no subsidiary is folded into a parent. A trial of two phases counts in both, and recruiting trials count as active.
- Name
- Array BioPharma
- Trials
- 28
- As lead sponsor
- 6
- As collaborator
- 22
- Recruiting
- 1
- Active, recruiting or not
- 3
- Completed
- 18
- Stopped early, withdrawn or suspended
- 6
- Posted results
- 9
- Trials by phase
- Phase 1 21, Phase 2 16
- Drugs its trials test
- 36
- Comparisons calculated in its trials
- 2
- First trial registered
- 2008-04-02
- Last update
- 2026-10-19
Source ClinicalTrials.gov
Pipeline36
The drugs its trials test, by the trial links the pipelines release's checks show. The phase is the highest phase those trials registered on ClinicalTrials.gov, not a development stage. Highest phase first, then the most trials.
| Drug | Highest phase registered | Trials | As lead sponsor | Recruiting | Targets | Mechanism | In Drugs and targets | Source |
|---|---|---|---|---|---|---|---|---|
| BINIMETINIB | Phase 2 | 18 | 1 | 1 | MAP2K1, MAP2K2 | Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor | https://conductscience.org/library/drugs/CHEMBL3187723 | Open Targets |
| ENCORAFENIB | Phase 2 | 6 | 3 | 0 | BRAF | Serine/threonine-protein kinase B-raf inhibitor | https://conductscience.org/library/drugs/CHEMBL3301612 | Open Targets |
| NIVOLUMAB | Phase 2 | 2 | 0 | 0 | PDCD1 | Programmed cell death protein 1 inhibitor | https://conductscience.org/library/drugs/CHEMBL2108738 | Open Targets |
| AVELUMAB | Phase 2 | 1 | 0 | 0 | CD274 | Programmed cell death 1 ligand 1 other | https://conductscience.org/library/drugs/CHEMBL3833373 | Open Targets |
| IMATINIB | Phase 2 | 1 | 0 | 1 | ABL1, BCR, KIT, PDGFRB | Bcr/Abl fusion protein inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase ABL inhibitor | https://conductscience.org/library/drugs/CHEMBL941 | Open Targets |
| SACITUZUMAB GOVITECAN | Phase 2 | 1 | 0 | 0 | TACSTD2, TOP1 | DNA topoisomerase I inhibitor; Tumor-associated calcium signal transducer 2 binding agent | https://conductscience.org/library/drugs/CHEMBL3545262 | Open Targets |
| CRIZOTINIB | Phase 1/2 | 2 | 0 | 0 | ALK, EML4, MET, MST1R, NPM1, ROS1 | ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor; Hepatocyte growth factor receptor inhibitor; Macrophage-stimulating protein receptor inhibitor; NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) inhibitor; Proto-oncogene tyrosine-protein kinase ROS inhibitor | https://conductscience.org/library/drugs/CHEMBL601719 | Open Targets |
| GEMCITABINE | Phase 1/2 | 2 | 1 | 0 | POLA1, POLA2, POLD1, POLD2, POLD3, POLD4, POLE, POLE2, POLE3, PRIM1, PRIM2, RRM1, RRM2, RRM2B | DNA polymerase (alpha/delta/epsilon) inhibitor; Ribonucleoside-diphosphate reductase RR1 inhibitor | https://conductscience.org/library/drugs/CHEMBL888 | Open Targets |
| BATOPROTAFIB | Phase 1/2 | 1 | 0 | 0 | PTPN11 | Protein-tyrosine phosphatase 2C inhibitor | https://conductscience.org/library/drugs/CHEMBL4650521 | Open Targets |
| CETUXIMAB | Phase 1/2 | 1 | 1 | 0 | EGFR | Epidermal growth factor receptor erbB1 inhibitor | https://conductscience.org/library/drugs/CHEMBL1201577 | Open Targets |
1 to 10 of 36
See all 36 pipelineTrials28
The trials that name the company as lead sponsor or collaborator, newest registered first. Results posted are as ClinicalTrials.gov gave them on the day of the sponsors capture.
| Trial | Title | Role | Phase | Status | Type | Participants | Start | Results first posted | Drugs | In Trials | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04598009 | Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma | Collaborator | Phase 2 | Recruiting | Interventional | 25 | 2021-03-03 | BINIMETINIB, IMATINIB | https://conductscience.org/library/trials/NCT04598009 | ClinicalTrials.gov | |
| NCT04375527 | Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma | Collaborator | Phase 2 | Terminated | Interventional | 3 | 2020-12-03 | BINIMETINIB, NIVOLUMAB | https://conductscience.org/library/trials/NCT04375527 | ClinicalTrials.gov | |
| NCT04292119 | Lorlatinib Combinations in Lung Cancer | Collaborator | Phase 1/2 | Unknown status | Interventional | 96 | 2020-05-01 | BATOPROTAFIB, BINIMETINIB, CRIZOTINIB, LORLATINIB | https://conductscience.org/library/trials/NCT04292119 | ClinicalTrials.gov | |
| NCT04074967 | Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab | Collaborator | Phase 1/2 | Active, not recruiting | Interventional | 70 | 2020-06-11 | IPILIMUMAB, NIVOLUMAB, PEXMETINIB | https://conductscience.org/library/trials/NCT04074967 | ClinicalTrials.gov | |
| NCT04005144 | Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer | Collaborator | Phase 1 | Terminated | Interventional | 3 | 2020-02-25 | BINIMETINIB, BRIGATINIB | https://conductscience.org/library/trials/NCT04005144 | ClinicalTrials.gov | |
| NCT03971409 | Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer | Collaborator | Phase 2 | Active, not recruiting | Interventional | 145 | 2019-07-08 | AVELUMAB, BINIMETINIB, SACITUZUMAB GOVITECAN | https://conductscience.org/library/trials/NCT03971409 | ClinicalTrials.gov | |
| NCT03843775 | A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers | Collaborator | Phase 1/2 | Completed | Interventional | 17 | 2019-02-14 | 2024-10-21 | BINIMETINIB, ENCORAFENIB | https://conductscience.org/library/trials/NCT03843775 | ClinicalTrials.gov |
| NCT03374254 | Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651) | Collaborator | Phase 1 | Completed | Interventional | 116 | 2018-02-16 | 2024-10-15 | BINIMETINIB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN, OXALIPLATIN, PEMBROLIZUMAB | https://conductscience.org/library/trials/NCT03374254 | ClinicalTrials.gov |
| NCT03231306 | Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas | Collaborator | Phase 2 | Completed | Interventional | 45 | 2017-11-28 | 2025-05-02 | BINIMETINIB | https://conductscience.org/library/trials/NCT03231306 | ClinicalTrials.gov |
| NCT03170206 | Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer | Collaborator | Phase 1 | Completed | Interventional | 34 | 2017-05-31 | BINIMETINIB, PALBOCICLIB | https://conductscience.org/library/trials/NCT03170206 | ClinicalTrials.gov |
1 to 10 of 28
See all 28 trialsConditions70
The conditions its trials name, as the trials write them, with case and spacing folded. The most trials first.
| Condition | Trials |
|---|---|
| Lung Cancer | 3 |
| Melanoma | 3 |
| Leukemia | 2 |
| Metastatic Colorectal Cancer | 2 |
| Non-Small Cell Lung Cancer | 2 |
| Solid Tumor | 2 |
| ALK Gene Rearrangement | 1 |
| AML | 1 |
| Advanced BRAF Mutant Cancers | 1 |
| Advanced Biliary Tract Carcinoma | 1 |
1 to 10 of 70Source ClinicalTrials.gov
See all 70 conditionsPartners43
The other organizations its trials name, as lead sponsor or collaborator, with the class ClinicalTrials.gov gives each. The most trials shared first. A partner that is a company opens its own record.
| Organization | Class | Trials shared | In Companies | Source |
|---|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | Other | 4 | ClinicalTrials.gov | |
| Pfizer | Industry | 4 | https://conductscience.org/library/companies/pfizer-69d9f765 | ClinicalTrials.gov |
| Breast Cancer Research Foundation | Other | 2 | ClinicalTrials.gov | |
| Dana-Farber Cancer Institute | Other | 2 | ClinicalTrials.gov | |
| M.D. Anderson Cancer Center | Other | 2 | ClinicalTrials.gov | |
| University of California, San Francisco | Other | 2 | ClinicalTrials.gov | |
| Beaumont Hospital | Other | 1 | ClinicalTrials.gov | |
| Belfast Health and Social Care Trust | Other | 1 | ClinicalTrials.gov | |
| Bristol-Myers Squibb | Industry | 1 | https://conductscience.org/library/companies/bristol-myers-squibb-1255780f | ClinicalTrials.gov |
| Celgene Corporation | Industry | 1 | https://conductscience.org/library/companies/celgene-corporation-caa7f5bb | ClinicalTrials.gov |
1 to 10 of 43
See all 43 partnersData dates
The date of each source this release read.
Sources 4
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL
- ClinicalTrials.govNo license stated
- Open TargetsCC0 1.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBLCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this company from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/companies/v1/array-biopharma-b2595afc
GET https://conductscience.org/api/companies/v1/array-biopharma-b2595afc/pipeline?page=2